TESTICULAR CANCER SOCIETY (EIN 273695606) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2010

Legal Domicile

Principal Officer

MICHAEL CRAYCRAFT

Phone

5136969827

Tax Period

2025-01-01 to 2025-12-31

TESTICULAR CANCER SOCIETY, founded in 2010, is a small nonprofit in the Diseases & Disorders sector that reported $124K in total revenue in fiscal year 2025. Revenue fell 26% from the prior year — a significant decline worth monitoring. Expenses of $209K exceeded revenue, resulting in a 68% operating deficit.

Mission

THE ORGANIZATION'S PRIMARY PURPOSE IS TO PROVIDE INCREASED AWARENESS ABOUT TESTICULAR CANCER, PROVIDE EDUCATION AND RESOURCES FOR TESTICULAR CANCER PATIENTS AND SURVIVORS AND TO PROVIDE AID AND SUPPORT OF RESEARCH AND TESTING RELATED TO TESTICULAR CANCER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $123,987

Program Service Revenue $0

Investment Income $0

Other Revenue $455

TOTAL REVENUE $124,442

Expense Breakdown

Grants Paid $6,022

Salaries & Benefits $161,476

Fundraising Expenses $9,538

Program Expenses $165,808

Other Expenses $41,267

TOTAL EXPENSES $208,765

Year-over-Year Comparison

	2025	2024	Change
Revenue	$124,442	$168,040	-0.3%
Expenses	$208,765	$157,969	+0.3%
Net Income	$-84,323	$10,071	-9.4%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$150,000

Total Directors

$150,000

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MICHAEL CRAYCRAFT	PRESIDENT/DIRECTOR	40.00	Officer Director	$150,000	$0	$150,000
DAVE FINKLANG	DIRECTOR	0.50	Director	$0	$0	$0
JASON HOGREFE	DIRECTOR	0.50	Director	$0	$0	$0
THAD SCHOEN	DIRECTOR	0.50	Director	$0	$0	$0
JEFF STUDENKA	DIRECTOR	0.50	Director	$0	$0	$0
ALEN AMINI	DIRECTOR	0.50	Director	$0	$0	$0
TONY GATTI	DIRECTOR	0.50	Director	$0	$0	$0
GARY KREIGH	TREASURER (FROM 2/4/2025)	0.50	Officer	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$124,442	$208,765	$292,226	$-84,323
2024	$168,040	$157,969	$376,549	$10,071
2023	$162,025	$187,187	$366,478	$-25,162
2022	$392,293	$180,365	$394,759	$211,928
2021	$216,084	$82,123	$182,841	$133,961

TESTICULAR CANCER SOCIETY